ClinicalTrials.gg
Status unknownNCT05612438RADIX 2Updated Nov 10, 2022

RADIX 2 RENAL STENT Post-Market Retrospective Study

An observational study in Renal Artery Stenosis and Renal Failure, sponsored by CID S.p.A.. Status unknown at 1 site in Italy. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-11-10.

Sponsored by CID S.p.A. · Observational

How we know

The sponsor has not verified this record recently (last verified Nov 2022), so the status shown — last known as Not yet recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
50
Ages
18 Years and older
Sex
All
01

Study summary

The Carbostent™ Radix 2 stent is a CE marked balloon expandable bare metal stent for the treatment of renal artery stenosis.

The aim of this post-market retrospective study protocol P12204, is to collect clinical data on patients treated with the RADIX 2 stent in routine clinical practice.

In order to obtain long-term follow-up data, the data collection will be limited to patients that have been treated with the Radix 2 stent at least 12 months prior to the study start.

Read the detailed description

The objective of this post-market study is collect retrospective clinical data on the implantable medical device Radix 2 stent in an unselected population treated in the current clinical practice. Data will be collected via medical chart review in anonymous form.

Radix2 is a bare metal balloon expandable stent with a progressive multicellular design for treatment of renal artery stenosis. The stent is stent coated with i-Carbofilm™ to accelerate the rate of endothelization and strut coverage.

The product is CE marked and commercially available since July 2010. Additional technical information on RADIX2 is available online: http://www.alvimedica.com/Product/15/bms-b-e-radix2

02

Conditions studied

  • Renal Artery Stenosis
  • Renal Failure
03

In context

Renal Artery Obstruction

59 studies on the registry are indexed under Renal Artery Obstruction; 10 are open to participants now.

This study's planned enrollment of 50 is below the median of 80 across 15 observational studies indexed under Renal Artery Obstruction.

Browse Renal Artery Obstruction studies →

Lead sponsor

CID S.p.A. is the lead sponsor of 7 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients affected with occlusive lesions of the native renal artery disease treated with the study stent, these patients are generally affected by cardiovascular comorbidities with a high incidence of mortality or in the terminal phase of the disease or in advanced age and in serious health conditions

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

The study will be conducted in the "real world" population, according to the following criteria.

Selection criteria:

  • Patient has been implanted with at least one study stent (Radix2) according to the indications described in the IFU.
  • Study Device Implanted is at least12 months prior to the starting date of the retrospective anonymous data collection.

Exclusion criteria

Exclusion Criteria:

  • Patients treated less than 12 months prior to study start
05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
50 participants (estimated)
Patient registry
No

Interventions

  • DeviceRADIX 2 Stent

    RADIX 2 stent implantation for the treatment of occlusive lesions of the native renal arteries; or in the case of inadequate results (residual stenosis \> 30%) or dissection of the vessel wall following PTRA procedure with or without stenting.

06

What researchers measure

Primary outcomes

  1. Major renal events

    Major renal events at 30 days - composite of: death from renal causes, related to study device or procedure; embolic events related to study device or procedure, resulting in kidney damage; acute kidney injury Stage 3 (AKIN criteria); ipsilateral nephrectomy, related to the study device or procedure.

    Time frame: 30 days

Secondary outcomes

  1. Acute device success

    Acute Device Success, defined as the successful delivery of the assigned device(s) to the designated target location

    Time frame: 24 hours

  2. Technical success

    Technical Success, defined as the ability to implant the stent with a residual angiographic stenosis no greater than 30%

    Time frame: 24 hours

  3. In Stent Restenosis

    Restenosis of Radix2 stent, requiring repeat revascularization

    Time frame: 12 months

  4. Arterial Blood Pressure

    Systolic and diastolic arterial blood pressure changes during follow-up

    Time frame: 12 months

07

Study locations

1 site
08

References and documents

Publications

  • Zeller T, Rastan A, Kliem M, Schwarzwalder U, Frank U, Burgelin K, Schwarz T, Amantea P, Muller C, Neumann FJ. Impact of carbon coating on the restenosis rate after stenting of atherosclerotic renal artery stenosis. J Endovasc Ther. 2005 Oct;12(5):605-11. doi: 10.1583/05-1599MR.1. PubMed 16212462 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Mar 2023; primary completion for Jul 2023, 4 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 4, 2022
First posted
Nov 10, 2022
StartEst.
Mar 3, 2023
Primary completionEst.
Jul 30, 2023
CompletionEst.
Aug 30, 2023
Last update
Nov 10, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 10, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05612438
Lead sponsor
CID S.p.A.
Collaborators
Meditrial Europe Ltd.
Responsible party
Sponsor
First posted
Nov 10, 2022
Start date
Mar 3, 2023 (estimated)
Primary completion
Jul 30, 2023 (estimated)
Completion
Aug 30, 2023 (estimated)
Last update
Nov 10, 2022

Study contacts

Franco Vallana, MD
Contact
franco.vallana@alvimedica.com
+39 0161 18261
Monica Tocchi, MD
Contact
m.tocchi@meditrial.net

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Nov 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion